Biotechnology

Radiopharm Theranostics

Radiopharm Theranostics' RAD 101 Trial Reaches 50% Enrollment May Initiate Global Phase 3 Trial

Radiopharm Theranostics Ltd. Starts Recruiting Patients for the Third Group of 177Lu-RAD204 Trial

Radiopharm Theranostics Ltd. Outlines Clinical Development Plans and Collaborates with MD Anderson

Radiopharm Theranostics Limited Receives Financial Support

Radiopharm Theranostics Ltd. Reports Early Positive Results from its Clinical Pipeline

Radiopharm Theranostics Receives Positive Recommendation for Clinical Trial

Radiopharm Theranostics Ltd. Collaborates with Starpharma to Develop Radiopharmaceutical Conjugate

Radiopharm Theranostics released FY2025 Annual Earnings on August 29 (EST), actual revenue USD 8.112 M (forecast USD 1.357 M), actual EPS USD -3.5833 (forecast USD -3.7922)

Radiopharm Theranostics released FY2025 Q3 earnings on August 29 (EST) with actual revenue of USD 3.446M and EPS of USD -0.7259

Radiopharm Theranostics released FY2025 Q4 earnings on August 29 (EST), actual revenue USD 3.287 M (forecast USD 1.294 M), actual EPS USD -0.8252

Radiopharm Theranostics released FY2025 9 Months Earnings on August 29, 2025 (EST) with actual revenue of USD 4.767M and EPS of USD -2.8035

Radiopharm Theranostics signs Cyclotek to support clinical trials for prostate cancer radiotherapy drug

Radiopharm Theranostics Ltd's RAD101 Receives FDA Breakthrough Therapy Designation

Radiopharm Theranostics Limited Announces Positive Preclinical Data for RV01

Radiopharm Theranostics Signs Erbium-177 Supply Agreement with ITM

Radiopharm Theranostics Ltd. Imaging Agent RAD 101 Shows Success in Brain Metastasis Detection Trials

Radiopharm Theranostics Launches 18F-RAD101 US Phase 2B Imaging Study

Radiopharm Theranostics released FY2025 Q1 earnings on February 28, 2025 (EST), with actual revenue of 841.57K USD and EPS of -1.0565 USD

Radiopharm Theranostics released FY2025 semi-annual earnings on February 28, 2025 (EST), with actual revenue of 1.601 M USD and EPS of -2.0096 USD

Radiopharm Theranostics released FY2025 Q2 earnings on February 28, 2025 (EST), with actual revenue of 758.12 K USD and EPS of -0.9517 USD

Treasure Gbl

SMX Security Matters

Wheeler Real Estate

Gulf Resources

DigitalBridge

Toro

Dreamland

Lichen

Springview

Alumis

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap